Clinical Trial Update: A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis [Phase 3]

View source ↗

Summary

Takeda is conducting a Phase 3 trial comparing Zasocitinib (TAK-279) with deucravacitinib in adults with plaque psoriasis. The study status is ACTIVE_NOT_RECRUI…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• Deucravacitinib (deucravacitinib)
• Zasocitinib (TAK-279) (zasocitinib)

Snippet

Sponsor: Takeda | Conditions: Plaque Psoriasis | Phase 3 | Status: ACTIVE_NOT_RECRUITING